Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBridge Biosciences (NBP) Total Debt (2018 - 2023)

NovaBridge Biosciences (NBP) has 4 years of Total Debt data on record, last reported at $4.2 million in Q4 2023.

  • On a quarterly basis, Total Debt rose 56.17% to $4.2 million in Q4 2023 year-over-year; TTM through Dec 2023 was $4.2 million, a 56.17% increase, with the full-year FY2023 number at $4.2 million, up 53.6% from a year prior.
  • Total Debt reached $4.2 million in Q4 2023 per NBP's latest filing, down from $4.3 million in the prior quarter.
  • Over the last five years, Total Debt for NBP hit a ceiling of $7.1 million in Q4 2019 and a floor of $2.7 million in Q4 2022.
  • A 3-year average of $4.6 million and a median of $4.2 million in 2023 define the central range for Total Debt.
  • Peak YoY movement for Total Debt: tumbled 38.69% in 2019, then soared 56.17% in 2023.
  • Tracing NBP's Total Debt over 3 years: stood at $7.1 million in 2019, then plummeted by 62.43% to $2.7 million in 2022, then skyrocketed by 56.17% to $4.2 million in 2023.
  • Business Quant data shows Total Debt for NBP at $4.2 million in Q4 2023, $4.3 million in Q2 2023, and $2.7 million in Q4 2022.